C4 Therapeutics, Inc.

US$3.10As of Sun 8 Nov 2026, 12:00 UTC
NASDAQ:CCCCHealthcare
Country USA
PE (Fwd) •••
TSR 6Y CAGR (29.18%)
Div yield —
ROE (48.14%)
Biotechnology
Beta (5Y) 3.16
PE TTM —
TSR TTM 18.77%
Mkt cap US$381.4M
ROIC (24.51%)
SE Grade™
Value
Quality
Moat
Consensus
Reference
$3.99
28.84%
54.29%
Hold 11|9|2|12|5
4Q25
1Q26
2Q26
3Q26
Earnings per share$
0.04
0.04
0.04
0.04
(0.74%)
(13.95%)
(10.49%)
(10.07%)
Revenue$M
44.22
46.32
46.58
45.73
15.64%
16.05%
13.05%
5.02%
Peers (US$381.4M)
Cap (US$)
PE
Capital
TTM
5Y
10Y
Leveragex
0.632
(0.126)
(0.120)
EBIT/Intx
14.22
0.139
0.135
Own earn%
58.94
(154.39)
(155.13)
Sh yield%
24.23
44.65
41.41
Owners
Insiders/Inst%
1.89
58.64
Short interest%
0.86
SBC / revenue%
2.44
Record
10Y
Profitable years
10/10
Revenue growth years
10/10
EPS growth years
10/10
Dividend streakyrs
18
Op margin range%
0–5
$1 testx
0.1
Incr. ROIC%
9